Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.39 --0%
Revenue Growth %: +32.0%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +32.0%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nomura/Instinet Upgrades SK Innovation Co Ltd (096770:KS) to Neutral
- Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
